The investigation and bioorthogonal anticancer activity enhancement of a triphenylphosphine-labile prodrug of seleno-combretastatin-4

Liyuan Hou; Wei Huang; Jiaqi Cheng; Xuanru Deng; Haoqiang Lai; Zhen Chen; Zepang Zhan; Pengju Feng; Yiqun Li; Fang Yang; Tianfeng Chen

doi:10.1039/D0CC05498D

The investigation and bioorthogonal anticancer activity enhancement of a triphenylphosphine-labile prodrug of seleno-combretastatin-4†

Liyuan Hou,‡^a Wei Huang,‡^a Jiaqi Cheng,

^a Xuanru Deng,^a Haoqiang Lai,^a Zhen Chen,^a Zepang Zhan,^a Pengju Feng,

*^a Yiqun Li,

*^a Fang Yang*^a and Tianfeng Chen

^a

Author affiliations

* Corresponding authors

^a Department of Chemistry, Jinan University, Guangzhou 510632, China
E-mail: pfeng@jnu.edu.cn, tlyq@jnu.edu.cn

Abstract

Here, a triphenylphosphine (TPP)-labile prodrug of seleno-combretastatin-4 (CSeD) was designed and synthesized. A detailed investigation revealed that CSeD, which was shown to be very safe in circulating blood, could react with TPP to release CA-4 and a selenodiazole derivative, with accompanying powerful anticancer and antiangiogenesis effects, as well as radiosensitization properties.

Chemical Communications

The investigation and bioorthogonal anticancer activity enhancement of a triphenylphosphine-labile prodrug of seleno-combretastatin-4†

Abstract

Supplementary files

Article information

Download Citation

Permissions

The investigation and bioorthogonal anticancer activity enhancement of a triphenylphosphine-labile prodrug of seleno-combretastatin-4

Social activity

Search articles by author

Spotlight

Advertisements